Latest News for: Pharmaceutical sources

Edit

Global Alpha Emitters Strategic Business Report 2022: Featuring Actinium Pharmaceuticals, Alpha Tau Medical, Bayer and ...

The Facts 07 Dec 2022
Actinium Pharmaceuticals, Inc.Alpha Tau MedicalBayer AGFusion PharmaIBA GroupIBA Radiopharma SolutionsLantheus Medical Imaging, Inc.NTP Radiosotopes SOC Ltd.RadioMedix, Inc.Siemens HealthineersTelix Pharmaceuticals Ltd.Triad Isotopes, Inc ... View source version on businesswire.com.https.//www.businesswire.com/news/home/20221207005424/en/ ... SOURCE.
Edit

Syndax Announces Proposed $150 million Public Offering of Common Stock

Eagle-Tribune 07 Dec 2022
WALTHAM, Mass., Dec. 6, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq ... LLC, J.P ... About Syndax Pharmaceuticals, Inc. Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies ... Syndax Pharmaceuticals, Inc ... SNDX-G ... SOURCE Syndax Pharmaceuticals, Inc.
Edit

Delta-Fly Pharma, Inc. is granted Orphan Drug Designation by US Food and Drug Administration for DFP-10917

The Galveston Daily News 07 Dec 2022
TOKUSHIMA, Japan--(BUSINESS WIRE)--Dec 7, 2022--. Delta-Fly Pharma, Inc ... Be given to ODD, Delta-Fly Pharma, Inc ... Capital ... Research and development, manufacturing and marketing of pharmaceuticals ... View source version on businesswire.com.https.//www.businesswire.com/news/home/20221206006153/en/ ... FDA HEALTH PHARMACEUTICAL CLINICAL TRIALS ONCOLOGY. SOURCE.
Edit

Syndax Announces Pricing of $150 Million Public Offering of Common Stock

Victoria Advocate 07 Dec 2022
6, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc ... Any offer, if at all, will be made only by means of a prospectus supplement and accompanying prospectus, which are a part of the effective registration statement.About Syndax Pharmaceuticals, Inc ... Syndax Pharmaceuticals, Inc ... SOURCE Syndax Pharmaceuticals, Inc.
Edit

Sallie Giblin Joins Alliant Insurance Services’ Employee Benefits Group in San Diego

The Joplin Globe 07 Dec 2022
IRVINE, Calif.--(BUSINESS WIRE)--Dec 6, 2022-- ... About Alliant Insurance Services ... View source version on businesswire.com.https.//www.businesswire.com/news/home/20221206006079/en/. CONTACT ... KEYWORD ... PROFESSIONAL SERVICES MANAGED CARE OTHER HEALTH HEALTH GENERAL HEALTH PHARMACEUTICAL HEALTH INSURANCE HOSPITALS INSURANCE HUMAN RESOURCES FINANCE. SOURCE ... .
Edit

BIOCORP Obtains 510(k) FDA Clearance for Mallya®

Eagle-Tribune 07 Dec 2022
ISSOIRE, France--(BUSINESS WIRE)--Dec 7, 2022--. Regulatory News. ... Eric Dessertenne, CEO of BIOCORP, said ... ” ... Mallya becomes the first system approved in the U.S ... View source version on businesswire.com.https.//www.businesswire.com/news/home/20221206005937/en/ ... HEALTH FDA MEDICAL DEVICES DIABETES HEALTH TECHNOLOGY PHARMACEUTICAL BIOTECHNOLOGY. SOURCE ... PUB.
Edit

Touchlight and Odimma Therapeutics Announce Clinical Material Supply Agreement to Develop Personalised Cancer Therapy Utilising ...

Eagle-Tribune 07 Dec 2022
HAMPTON, England--(BUSINESS WIRE)--Dec 7, 2022-- ... The program is expected to start clinical enrolment in 2023 ... - ENDS -. About Touchlight ... View source version on businesswire.com.https.//www.businesswire.com/news/home/20221206005579/en/. CONTACT. At Touchlight ... SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL ONCOLOGY HEALTH GENETICS CLINICAL TRIALS. SOURCE ... .
Edit

United States Pharmaceuticals Regulatory Intelligence Report 2022: Requirements for Pharmaceuticals Marketing and Registration - ResearchAndMarkets.com

The Facts 06 Dec 2022
The "Regulatory Intelligence Report for Pharmaceuticals in the U.S." ... The current report provides detailed exposure to regulatory requirements for pharmaceuticals marketing and registration in the USA ... These regulations would be helpful for the premarketing of the pharmaceutical in the U.S ... 1.3 Information Sources ... BIOTECHNOLOGY PHARMACEUTICAL HEALTH.
Edit

Cosette Pharmaceuticals Announces the launch of Griseofulvin Oral Suspension, 125 mg/5 mL.

Hastings Tribune 06 Dec 2022
Cosette Pharmaceuticals, Inc ("Cosette") began shipping Griseofulvin Oral Suspension, 125 mg/5 mL (0713-0850-04) into all channels in the United States ... Apurva Saraf, President and CEO, Coesette Pharmaceuticals ... About Cosette Pharmaceuticals, Inc... Cosette Pharmaceuticals, Inc ... GENERAL HEALTH PHARMACEUTICAL HEALTH. SOURCE. Cosette Pharmaceuticals, Inc.
Edit

Recombinant Proteins Market Report 2022: Increasing Government Investments and Rising Focus on Personalized Medicine to ...

Eagle-Tribune 06 Dec 2022
The market growth is primarily driven by factors such as increasing government investments and R&D expenditure in pharmaceutical & biotechnology companies and academic research institutes alongside the high prevalence of chronic and infectious diseases resulting in the need for recombinant proteins for crucial diagnostics ... SOURCE.
Edit

New Report from BluesightⓇ Sheds Light on U.S. Consumer Trust in Healthcare and Pharmaceutical Management

The Galveston Daily News 06 Dec 2022
healthcare system and pharmaceutical industry, which revealed that trust in both is below average ... Trust in pharmaceutical companies also has a long way to go, with 45.43% of respondents reporting that they do not trust them ... Trust in Pharmaceutical Management within Healthcare Systems survey was distributed to U.S ... SOURCE.
Edit

Shuttle Pharmaceuticals Manuscript Published in Cancer Research Communications

Victoria Advocate 06 Dec 2022
6, 2022 /PRNewswire/ --�Shuttle Pharmaceuticals Holdings, Inc ... Chief at Shuttle Pharmaceuticals ... Mira Jung, PhD is a Co-Founder & Scientific Director of Shuttle Pharmaceuticals ... About Shuttle Pharmaceuticals ... Shuttle Pharmaceuticals ... SOURCE Shuttle Pharmaceuticals Holdings, Inc.
Edit

Avalon BioVentures Raises First Fund Dedicated to Early-Stage Biotech Investments

The Facts 06 Dec 2022
Vertex Pharmaceuticals, Onyx Pharmaceuticals, Amira Pharmaceuticals, and Neurocrine Biosciences ... View source version on businesswire.com.https.//www.businesswire.com/news/home/20221206005242/en/ ... BIOTECHNOLOGY FINANCE HEALTH PROFESSIONAL SERVICES PHARMACEUTICAL. SOURCE.
Edit

MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for ...

The Facts 06 Dec 2022
MyMD Pharmaceuticals, Inc.® (Nasdaq ... About MyMD Pharmaceuticals. MyMD Pharmaceuticals, Inc ... View source version on businesswire.com.https.//www.businesswire.com/news/home/20221206005205/en/ ... RESEARCH CLINICAL TRIALS BIOTECHNOLOGY OTHER HEALTH MANAGED CARE HEALTH PHARMACEUTICAL OTHER SCIENCE SCIENCE. SOURCE. MyMD Pharmaceuticals, Inc.
Edit

ADDING MULTIMEDIA MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British ...

News-Press Now 06 Dec 2022
MyMD Pharmaceuticals, Inc.® (Nasdaq ... About MyMD Pharmaceuticals. MyMD Pharmaceuticals, Inc ... View source version on businesswire.com.https.//www.businesswire.com/news/home/20221206005205/en/ ... RESEARCH CLINICAL TRIALS BIOTECHNOLOGY OTHER HEALTH MANAGED CARE HEALTH PHARMACEUTICAL OTHER SCIENCE SCIENCE. SOURCE. MyMD Pharmaceuticals, Inc.

Most Viewed

President Cristina Fernandez de Kirchner at her second Inauguration day
Creative Commons / Presidency of Argentina.
Members of the Inter-American Commission on Human Rights group go to the Simón Bolívar International Bridge
Creative Commons / cidh https://creativecommons.org/licenses/by/2.0/
×